ALS Trials
Search for a Trial

Search for a Trial

With help from The ALS Association, NEALS provides up-to-date information for finding both federally and privately funded clinical studies focusing on ALS and motor neuron diseases. You can locate both interventional trials, which examine if treatments are effective and safe under controlled environments, and observation trials, which examine people in more natural environments.

NEALS sources this database from public information posted on www.clinicaltrials.gov and other public websites. Therefore, not all trials included here are endorsed by The ALS Association and/or NEALS. Trials with a NEALS emblem are those in which NEALS has a supporting role. This database is updated regularly, so please check back. If you need support please contact our ALS Trial Liaison at (855) 437-4823 or alstrials@neals.org.

You may also want to try searching for trials using Antidote or I AM ALS Signal: Clinical Research Dashboard.

Phase iii Interventional trials

Trial Name	Coordinating Center Location
{relevance_count}A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (Phoenix)	View all locations
{relevance_count}A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)	View all locations
{relevance_count}A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)	View all locations
{relevance_count}A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)	View all locations
{relevance_count}A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)	View all locations
{relevance_count}A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)	View all locations
{relevance_count}HEALEY ALS Platform Trial	Boston, Massachusetts View all locations
{relevance_count}A Randomised, Double-blind, Single-centre Study on the Safety, Tolerability and Efficacy of Cannabis Based Medicine Extract (CannTrust CBD Oil) in Slowing the Disease Progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Patients	Gold Coast, Queensland View all locations
{relevance_count}A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients	View all locations

Phase ii Interventional trials

Trial Name	Coordinating Center Location
{relevance_count}A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis	View all locations
{relevance_count}A 6-Month Extension Study Following Protocol VMALS-002-2 (A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis)	View all locations
{relevance_count}A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD)	View all locations
{relevance_count}A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS	View all locations
{relevance_count}A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic L	View all locations
{relevance_count}A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis	View all locations
{relevance_count}A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)	View all locations
{relevance_count}A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis	View all locations
{relevance_count}A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)	View all locations
{relevance_count}A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS	View all locations
{relevance_count}A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by an Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis	View all locations
{relevance_count}HEALEY ALS Platform Trial	Boston, Massachusetts View all locations
{relevance_count}An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography	View all locations
{relevance_count}A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS. (RESCUE-ALS)	View all locations
{relevance_count}A Single-Center, Open Label Study to Assess the Safety and Tolerability of Metformin in Subjects With C9orf72 Amyotrophic Lateral Sclerosis Over 24 Weeks of Treatment	Gainesville, Florida View all locations
{relevance_count}A Phase II Randomized, Placebo-Controlled, Double Blinded, Multi-Centre Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis	Calgary, Alberta View all locations
{relevance_count}Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study	, New Hampshire View all locations
{relevance_count}A Phase II Study of Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis	Rochester, Minnesota View all locations

other interventional trials

Trial Name	Coordinating Center Location
{relevance_count}Effects of Remote Ischemic Conditioning on Hand Use in Individuals With Spinal Cord Injury and Amyotrophic Lateral Sclerosis: A Preliminary Study	Bronx, New York View all locations
{relevance_count}Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS	West Lafayette, Indiana View all locations
{relevance_count}Remotely Supervised Transcranial Direct Current Stimulation for Slowing Disease Progression in Amyotrophic Lateral Sclerosis (ALS)	Chicago, Illinois View all locations
{relevance_count}ECoG for Motor and Speech Control (BRAVO)	San Francisco, California View all locations
{relevance_count}Brain-Computer Interface Implant for Severe Communication Disability	Baltimore, Maryland View all locations
{relevance_count}Remote Pulmonary Function Testing and Nurse Respiratory Health Coaching in Amyotrophic Lateral Sclerosis	Hershey, Pennsylvania View all locations
{relevance_count}Electrical Impedance Myography: Exploratory Studies in Normal Subjects and Patients With Neuromuscular Disorders	Bethesda, Maryland View all locations
{relevance_count}Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS: A Pilot Study	New York, New York View all locations
{relevance_count}Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease	Gainesville, Florida View all locations
{relevance_count}Investigation on the Cortical Communication (CortiCom) System	Baltimore, Maryland View all locations
{relevance_count}Understanding Communication and Cognitive Impairments in Neurodegenerative Disorders	Columbia, Missouri View all locations
{relevance_count}A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)	New York, New York View all locations
{relevance_count}BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia	Boston, Massachusetts View all locations
{relevance_count}Exploratory Evaluation of [11C]MPC6827 Pharmacokinetics With Positron Emission Tomography (PET)	New York, New York View all locations
{relevance_count}A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, Followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis	Leiden View all locations
{relevance_count}A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS	View all locations
{relevance_count}A Phase 1 Study to Assess the Safety and Tolerability of PET Imaging With [11C]CPPC [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] Radioligand in Patients With Amyotrophic Lateral Sclerosis	Baltimore, Maryland View all locations
{relevance_count}A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene	View all locations
{relevance_count}Phase I Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) for Amyotrophic Lateral Sclerosis	View all locations
{relevance_count}A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis	New York, New York View all locations
{relevance_count}HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	Bethesda, Maryland View all locations

observational studies

Trial Name	Coordinating Center Location
PATHOGENESIS IN C9ORF72-RELATED ALS (PiCALS)	Atlanta, Georgia View all locations
Intermuscular Coherence: A Biomarker for Early Diagnosis and Follow-up of ALS	View all locations
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders	Jacksonville, Florida View all locations
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At - Home Measures	View all locations
Analysis of Human ALS Tissues and Registry of ALS Patients	Chicago, Illinois View all locations
ALS Sample Repository	Boston, Massachusetts View all locations
A Longitudinal Analysis of Biomarkers in Patients with ALS	View all locations
Microbiome in the Progression of ALS (MPALS)	Atlanta, Georgia View all locations
Phenotype, Genotype and Biomarkers 2	Miami, Florida View all locations
A Single or Multiple Visit Protocol for Collection of DNA/RNA/Serum/Plasma/CSF in Amyotrophic Lateral Sclerosis and related disorders	Solana Beach , California View all locations
Smartphone Application to Track the Progression of ALS and Related Motor Neuron Diseases	Baltimore, Maryland View all locations
University of Pennsylvania Centralized Observational Research Repository on Neurodegenerative Disease (UNICORN)	Philadelphia, Pennsylvania View all locations
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry	Charlotte, North Carolina View all locations
An Observational Study to Assess Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing	Bethesda, Maryland View all locations
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)	View all locations
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Amyotrophic Lateral Sclerosis	Ventura, California View all locations
Oxidative Markers and Efficacy in Amyotrophic Lateral Sclerosis (ALS) Phenotypes Treated With Edaravone	Loma Linda, California View all locations
Radicava/(Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)	Boston, Massachusetts View all locations
The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)	Boston, Massachusetts View all locations
Real World Testing of a Brain-Computer Interface to Operate a Commercial Augmentative and Alternative Communication System	Pittsburgh, Pennsylvania View all locations
TRIAL READY (Clinical Trial Readiness)	Miami, Florida View all locations
Amyotrophic Lateral Sclerosis (ALS) Families Project	New York, NY View all locations
Clinical Procedures to Support Research in ALS (CAPTURE-ALS)	Miami, Florida View all locations
Glial Activation Measured by PBR28-PET in People with Neurogenerative Disease	Boston, Massachusetts View all locations
Genetic Characterization of Movement Disorders and Dementias	View all locations
Novel MRI Biomarkers for Monitoring Disease Progression in ALS	View all locations
SOD1 Kinetics Measurements in ALS Patients	St. Louis , Missouri View all locations
The DIALS (Dominant Inherited ALS) Network	Boston, Massachusetts View all locations
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia	Bethesda, Maryland View all locations
Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS	Ann Arbor, Michigan View all locations
Delineating Physiologic Mechanisms of Swallowing Impairment and Decline in ALS	Gainesville, Florida View all locations
Feasibility and Sensitivity of a Symptom Monitoring Application in Real Time (SMART) for ALS	Boston, Massachusetts View all locations
Quantitative Ultrasonography and Electrical Impedance Myography: Speech and Swallowing Technologies for Use in Neurological Disorders	Boston, Massachusetts View all locations
Clinical Research in ALS	Miami, Florida View all locations
Innovative Ultrasound Technology in Neuromuscular Disease (AQUIRe)	Boston, Massachusetts View all locations
The National Amyotrophic Lateral Sclerosis Registry	Atlanta, Georgia View all locations
Stem Cells for Research in Motor Neuron Disease	Boston, Massachusetts View all locations
Clinical and Molecular Manifestations of Inherited Neurological Disorders	Bethesda, Maryland View all locations
Family Studies in Neuromuscular Disorders	Worcester, Massachusetts View all locations
Identification of Genes Causing Familial ALS or Increasing Risk for Sporadic ALS and ALS With Frontotemporal Dementia and Understanding Disease Mechanism	Chicago, Illinois View all locations
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study	Miami, Florida View all locations

Trial Name	Coordinating Center Location	Status
A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis	View all locations	Enrolling
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (Phoenix)	View all locations	Enrolling
A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD)	View all locations	Enrolling
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis	View all locations	Enrolling
A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)	View all locations	Enrolling
A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)	View all locations	Enrolling
A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)	View all locations	Enrolling
HEALEY ALS Platform Trial	Boston, Massachusetts View all locations	Enrolling
Radicava/(Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)	Boston, Massachusetts View all locations	Enrolling
Phase 2a Study of the Expansion and Infusion of Autologous T-Regulatory Cells in Amyotrophic Lateral Sclerosis	Houston, Texas View all locations	Not enrolling
The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)	Boston, Massachusetts View all locations	Enrolling
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis	View all locations	Not enrolling
A Clinical Trial of Creatine in ALS	View all locations	Not enrolling
Tolerance of high-dose coenzyme Q10 in ALS	View all locations	Not enrolling
Trial of Celecoxib in Amyotrophic Lateral Sclerosis	View all locations	Not enrolling
Generation and characterization of cell lines for amyotrophic lateral sclerosis	Baltimore, Maryland View all locations	Not enrolling
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With ALS and Confirmed Superoxide Dismutase 1 Mutation (VALOR)	View all locations	Not enrolling
Effect of Oral Levosimendan (ODM-109) on Respiratory Function in Patients with ALS (REFALS)	Boston, Massachusetts View all locations	Not enrolling
Expanded Access Use of microRNA Delivered Intrathecally via Adeno-Associated Virus rh10 as Therapy for Mutant SOD1 Mediated Amyotrophic Lateral Sclerosis (ALS)	Boston, Massachusetts View all locations	Not enrolling
The DIALS (Dominant Inherited ALS) Network	Boston, Massachusetts View all locations	Enrolling
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With ALS (FORTITUDE-ALS)	View all locations	Not enrolling
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (SURE-ALS2)	Boston, Massachusetts View all locations	Not enrolling
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS (CENTAUR)	Boston, Massachusetts View all locations	Not enrolling
ALS Testing through Home-Based Outcome Measures (ALS AT HOME)	Phoenix, Arizona View all locations	Not enrolling
Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis	Los Angeles, California View all locations	Not enrolling
A Study to Evaluate the Sensitivity, Specificity, and Overall Accuracy of an Amyotrophic Lateral Sclerosis Diagnostic Test Developed by Iron Horse Diagnostics	Cleveland, Ohio View all locations	Not enrolling
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation	View all locations	Not enrolling
Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS)	Boston, Massachusetts View all locations	Not enrolling
Genomic Translation for Amyotrophic Lateral Sclerosis Care	New York, New York View all locations	Not enrolling
Fluid Biomarkers with Deep Phenotyping in Patients with ALS (ALSA-BIO3)	Phoenix, Arizona View all locations	Not enrolling
Open-Label, Proof-of-Mechanism Trial of Ibudilast Treatment in people with Amyotrophic Lateral Sclerosis (ALS)	Boston, Massachusetts View all locations	Not enrolling
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS	St. Louis, Missouri View all locations	Not enrolling
A Pilot Study of Inosine in ALS	Boston, Massachusetts View all locations	Not enrolling
Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance	Boston, Massachusetts View all locations	Not enrolling
The Natural History of SOD1 Amyotrophic Lateral Sclerosis	St. Louis, Missouri View all locations	Not enrolling
Longitudinal Study Comparing the Responsiveness of Outcomes Measures in ALS Trials	Boston, Massachusetts View all locations	Not enrolling
A Safety and Tolerability Study of Mexiletine in Patients with Sporadic ALS (SALS)	Boston, Massachusetts View all locations	Not enrolling
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis	Boston, Massachusetts View all locations	Not enrolling
The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)	Boston, Massachusetts View all locations	Not enrolling
Microbiome Assessment in People with ALS (MAP ALS)	Boston, Massachusetts View all locations	Not enrolling
Cross-Sectional ALS Biofluid Biomarker (CABB) Study	Boston, Massachusetts View all locations	Not enrolling
Answer ALS: Individualized Initiative for ALS Discovery	Boston, Massachusetts View all locations	Not enrolling
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)	Boston, Massachusetts View all locations	Not enrolling
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis (TRACK-ALS)	Boston, Massachusetts View all locations	Not enrolling
A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (VITALITY-ALS)	View all locations	Not enrolling
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects	Boston, Massachusetts View all locations	Not enrolling
Electronic-health Application To Measure Outcomes REmotely Clinical Trial (EAT MORE)	Boston, Massachusetts View all locations	Not enrolling
A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis	Boston, Massachusetts View all locations	Not enrolling
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) (IBU-ALS-1201)	Charlotte, North Carolina View all locations	Not enrolling
Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS) In Participants with Amyotrophic Lateral Sclerosis (ALS)	Boston, Massachusetts View all locations	Not enrolling
A Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis (ALS)	Boston, Massachusetts View all locations	Not enrolling
A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis	Atlanta, Georgia View all locations	Not enrolling
Analysis of Immune Activation in the Peripheral Blood of Patients with ALS	Boston, Massachusetts View all locations	Not enrolling
Magnetic Resonance Spectroscopy in Amyotrophic Lateral Sclerosis	Charlestown, Massachusetts View all locations	Not enrolling
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)	View all locations	Not enrolling
A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	, Massachusetts View all locations	Not enrolling
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Syracuse, New York View all locations	Not enrolling
Validation of a New Device to Measure Neuromuscular Disease Progression	Charlestown, Massachusetts View all locations	Not enrolling
A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, & Pharmacokinetics of ISIS333611 Administered Intrathecally to Patients w Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutation	Charlestown, Massachusetts View all locations	Not enrolling
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)	Charlestown, Massachusetts View all locations	Not enrolling
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) (BIO_ALS-01)	Boston, Massachusetts View all locations	Not enrolling
Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)	View all locations	Not enrolling
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)	View all locations	Not enrolling
Stem Cells for Research in Motor Neuron Disease	Boston, Massachusetts View all locations	Enrolling
Assessing Activation of Brain Microglia in ALS with Simultaneous MR-PET	Boston, Massachusetts View all locations	Not enrolling
Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)	Baltimore, Maryland View all locations	Not enrolling
A Multicenter Study for the Discovery and Validation of ALS Biomarkers (BIO_ALS-02)	Boston, Massachusetts View all locations	Not enrolling
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis	View all locations	Not enrolling
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis	Miami, Florida View all locations	Not enrolling
Trial of High fat/High Calorie Diet versus Optimal Nutrition in Amyotrophic Lateral Sclerosis	Charlestown, Massachusetts View all locations	Not enrolling
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study	Miami, Florida View all locations	Enrolling
A Phase I, Open-label, First-in-human Feasibility and Safety Study of Human Spinal Cord derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis	Charlestown, Massachusetts View all locations	Not enrolling
Clinical Trial for Ceftriaxone in Subjects with ALS	Charlestown, Massachusetts View all locations	Not enrolling

Search for a Trial

Study Factors

Disease:

Study Status:

Type of Study:

Study Category:

Study Phase:

Location:

Date Study Last Updated:

Date Study Posted:

Eligibility Factors

Gender:

Time Since Symptom Onset:

Vital Capacity:

Time Since Diagnosis: